An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16)

First published 25/08/2023

Last updated 15/07/2024

EU PAS number:

EUPAS106401

Study

Ongoing

Documents

Study protocol

Initial protocol

C1071016_Protocol_Elranatamab NIS_V1.0_31Aug2023_FINAL_redacted.pdf

English (800.55 KB - PDF)View document

Updated protocol

C1071016_Protocol_Elranatamab NIS_V2.0_04Jun2024_FINAL_Signed_Redacted.pdf

First published: 12/07/2024

English (950.05 KB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs